There are no products in your shopping cart.
Cognistat is a screening and assessment tool for rapid testing of patients for the full spectrum of cognitive deficits, including delirium, MCI and dementia.
Cognistat has been fully validated for
adults (20 – 59)
seniors (60 – 84)
Cognistat can be used by any suitably trained health care professional.
Cognistat is a domain specific test instrument that provides individual scores in the five major cognitive domains: language, spatial skills, memory, calculations and reasoning.
There is a great need for a simple and reliable tool for screening elderly patients for cognitive decline – ideally on an annual basis. Cognistat with its 20 minute examination of all the cognitive areas and a 5 minute examination for Mild Cognitive Impairment is the ideal test instrument to fill this need. The computer-assisted versions of Cognistat permit the easy visual comparison of annual test data to rapidly detect changes.
There are two versions of Cognistat:
The original 20-minute Multi-domain Cognitive Instrument: It looks at all the possible cognitive deficits that might be found in most patients. Cognistat is unique in cognitive testing in that it preserves the test scores for each individual domain and presents them to the user in a graphical format that permits easy year over year comparison.
The 5-minutes mini Cognitive Test: With the need for a specific screening instrument for Mild Cognitive Impairment (MCI), Cognistat introduced Cognistat Five, a new more rapid test requiring only 5 minutes of patient time. This version examines a reduced subset of cognitive domains specifically sensitive to MCI. Its primary application will be in screening for Delirium, MCI and Dementia. It should also find application in hospital admission and discharge as a means for establishing clinical baselines.
“Cognistat continues to be a valuable tool in our preventive medicine program. For many patients the Cognistat assessment provides powerful reassurance that there is no evidence to confirm their fears of early dementia. For others, serial testing has demonstrated clear evidence of cognitive decline. With objective evidence I've been able to proceed with a formal evaluation, appropriate treatment and lifestyle management. The assessment fits easily in to a busy practice and offers actionable information.”
Richard Abrams, MD
"Because I conduct assessments in various locations (and not just my office) I use both versions and find them very usxeful with screening for neurocognitive concerns."
Michael O'Brien PsyD., HSPP
“The Cognistat is a basic screening instrument that tests several important domains of the patient's cognitive abilities.”
Linda Josef Ph.D.